Cuban scientists have received international recognition for a lung cancer vaccine that has demonstrated promising results in extending survival for patients with advanced non-small cell lung cancer. The vaccine, known as Vaxira (Racotumomab), was awarded the Technological Innovation Prize-2025 by Cuban authorities, highlighting its significance in the country’s medical innovation landscape.
Developed by the Molecular Immunology Center (CIM), Vaxira is an active immunotherapy designed to stimulate a specific humoral immune response against the ganglioside NGlycolyl GM3, a tumor-specific antigen present in more than 90 percent of non-small cell lung tumors. This mechanism enables the vaccine to induce an immune response that targets cancer cells expressing this antigen, leading to tumor cell lysis through a process known as oncosis, characterized by the formation of holes in the tumor cell membrane.
According to clinical follow-up data from over 1,300 patients treated between 2013 and 2023, Vaxira has shown a median survival of 76.6 months, with approximately 20 percent of treated patients experiencing unexpected long-term survival. The treatment is indicated for patients who have responded to first-line oncology therapy and are in the maintenance phase of advanced disease, offering a strategy to control tumor progression and improve quality of life.
The vaccine’s safety profile has been reinforced through years of monitoring, with no new adverse events reported beyond those identified in earlier studies. Its administration has been deemed feasible in primary healthcare settings, underscoring its potential for broader accessibility within Cuba’s public health system.
Vaxira represents one of several Cuban-developed immunotherapies targeting lung cancer. Another notable example is CIMAvax-EGF, a vaccine co-developed by the Molecular Immunology Center and the Center for Genetic Engineering and Biotechnology (CIGB). CIMAvax-EGF works by inducing antibodies against epidermal growth factor (EGF), a protein that promotes cancer cell growth. By reducing circulating EGF levels, the vaccine aims to slow tumor proliferation. It has been used in clinical settings in countries including Cuba and, under special arrangements, in the United States for patients with advanced lung cancer.
Both Vaxira and CIMAvax-EGF reflect Cuba’s sustained investment in biotechnology and immunology despite economic challenges. These vaccines have been developed through decades of research focused on leveraging the body’s immune system to combat cancer, offering alternatives to conventional treatments such as chemotherapy and radiation.
The recognition of Vaxira with the Technological Innovation Prize-2025 underscores the ongoing contributions of Cuban scientific institutions to global oncology research. As lung cancer remains a leading cause of cancer-related mortality worldwide, such innovations continue to attract attention for their potential to complement existing therapeutic approaches.
For updates on regulatory status, clinical trial results, or availability of Cuban-developed cancer vaccines, individuals are encouraged to consult official communications from the Molecular Immunology Center, the Center for Genetic Engineering and Biotechnology, or Cuba’s Ministry of Public Health.
We welcome your thoughts and insights on this development. Sense free to share your comments below or spread the word on social media to help inform others about advances in global health innovation.